EP.12A.03 Overall survival after treatment with first-line osimertinib for EGFR-mutant advanced NSCLC in the US

2024

Sabari JK, Yu HA, Mahadevia P, Liu Y, Demirdjian L, Sultan AA, Chen YH, Wang X, Passaro A